Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists

Lallemand, Christophe; Kavrochorianou, Nadia; Steenholdt, Casper; Bendtzen, Klaus; Ainsworth, Mark; Méritet, Jean–François; Blanchard, Brigitte; Lebon, Pierre; Taylor, Peter; Charles, Peter; Alzabin, Saba; Tovey, Michaël G.

doi:10.1016/j.jim.2011.08.022

Cited by 86 publications

(58 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the reported gene assay has been developed as an alternative to the aforementioned approaches [80]. This cell-based assay was developed for the quantification of the activity and neutralizing antibody response to TNF-α agents and uses human erythtroleukemic K652 cells transfected with a NFkB regulated firefly luciferase reporter-gene construct.…”

Section: Discussionmentioning

confidence: 99%

New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis

Meroni¹,

Valentini²,

Ayala³

et al. 2015

Autoimmunity Reviews

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis

Meroni¹,

Valentini²,

Ayala³

et al. 2015

Autoimmunity Reviews

View full text Add to dashboard Cite

“…2,10 We therefore aimed at comparing basic analytical properties including level of agreement of commonly used ELISA and RIA techniques for detection of IFX and anti-IFX Abs and to compare these data with those of a recently developed cell-based reporter gene assay (RGA) and a new enzyme immunoassay (EIA) for anti-IFX Ab. 12,13 MATERIALS AND METHODS…”

Section: Introductionmentioning

confidence: 99%

Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease

Steenholdt

Ainsworth

Tovey

et al. 2013

Therapeutic Drug Monitoring

Self Cite

105

View full text Add to dashboard Cite

show abstract

“…In this approach, genetic engineering techniques are used to put firefly luciferase under a specific promoter and modifications are made to maximize reporter gene expression (12). Figure 5 illustrates an example of the iLite construct as applied to tumor necrosis factor alpha (TNF-α) (13). In this example, in the presence of TNF-α in the sample, luciferase enzyme is produced.…”

Section: Ilitementioning

confidence: 99%

Next Generation Ligand Binding Assays—Review of Emerging Technologies’ Capabilities to Enhance Throughput and Multiplexing

Mora

Chunyk

Dysinger

et al. 2014

AAPS J

View full text Add to dashboard Cite

Abstract. The purpose of this manuscript is to provide a summary of the evaluation done by the Throughput and Multiplexing subteam on five emerging technologies: Single molecule array (Simoa™), Optimiser™, CyTOF® (Mass cytometry), SQIDLite™, and iLite™. Most of the information is presented with a minimum amount of published data and much is based on discussions with users and the vendor, to help provide the reader with an unbiased assessment of where the subteam sees each technology fitting best in the bioanalysis of large molecules. The evaluation focuses on technologies with advantages in throughput and multiplexing, but is wide enough to capture their strengths in other areas. While all platforms may be suited to support bioanalysis in the discovery space, because of their emergent nature, only Optimiser and SQIDLite are currently ready to be used in the regulated space. With the exception of Optimiser, each instrument/technology requires an up-front investment from the bioanalytical lab that will need justification during capital budget discussions. Ultimately, the platform choice should be driven by the quality of data, project needs, and the intended use of the data generated. In a time-and resourceconstrained environment, it is not possible to evaluate all emergent technologies available in the market; we hope that this review gives the reader some of the information needed to decide which technology he/ she may want to consider evaluating to support their drug development program in comparison to the options they already have in their hands.

show abstract

Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists

Cited by 86 publications

References 25 publications

New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis

New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis

Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease

Next Generation Ligand Binding Assays—Review of Emerging Technologies’ Capabilities to Enhance Throughput and Multiplexing

Contact Info

Product

Resources

About